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        Cytokines that signal via the common      chain 
(    c) represent promising therapeutics based on 
their potential to augment T cell expansion and 
increase the eff  ectiveness of immune-based 
therapies (  1  –  6  ). Within this family, IL-2 is a 
prototypic activating cytokine, secreted by and 
selectively signaling activated T cells, as well 
as up-regulating its own receptor (IL-2R). In 
contrast, IL-7 is a prototypic homeostatic cyto-
kine, produced constitutively by nonlymphoid 
cells. Its receptor (IL-7R    ) is expressed on 
resting T cells, and then rapidly down-regulated 
after T cell activation or IL-7 signaling (  7  ). IL-7 
is essential for T cell development in mice 
(  8  –  10  ) and humans (  11, 12  ), as well as for 
T cell homeostasis, because it is required to 
maintain naive CD4  +   and CD8  +   T cells in vivo 
(  13, 14  ). IL-7 levels rise in serum and tissues 
after T cell depletion and fall upon recovery 
(  14  –  16  ). 
  In preclinical studies, IL-7 therapy exerts 
marked eff  ects on T cell immune reconstitu-
tion in mice (  17  ) and primates (  18  –  20  ). IL-7 
augments eff  ector and memory responses to 
vaccination in mice (  21  ) with preferential en-
hancement of responses to weak subdominant 
antigens. In preclinical models, IL-7 therapy 
CORRESPONDENCE  
 Claude  Sport è s: 
   csportes@mail.nih.gov
  Abbreviations used: CT, com-
puterized tomography;     c, 
common      chain; rh, recombi-
nant human; MFI, mean fl  uo-
rescence intensity; RTE, recent 
thymic emigrant; TREC, TCR 
excision circle. 
  R.E. Gress and C.L. Mackall contributed equally to this paper. 
      The online version of this article contains supplemental material.   
  Administration of rhIL-7 in humans 
increases in vivo TCR repertoire diversity by 
preferential expansion of naive T cell subsets 
    Claude     Sport  è  s  ,    1       Frances T.     Hakim  ,    1       Sarfraz A.     Memon  ,    1       Hua     Zhang  ,    2     
  Kevin S.     Chua  ,    2       Margaret R.     Brown  ,    4       Thomas A.     Fleisher  ,    4     
  Michael C.     Krumlauf  ,    1       Rebecca R.     Babb  ,    1       Catherine K.     Chow  ,    3     
  Terry J.     Fry  ,    2       Julie     Engels  ,    5       Renaud     Buff  et  ,    5       Michel     Morre  ,    5     
  Robert J.     Amato  ,    6       David J.    Venzon  ,    7       Robert     Korngold  ,    8       Andrew     Pecora  ,    8     
  Ronald E.     Gress  ,    1     and   Crystal L.     Mackall      2     
  1  Experimental Transplantation and Immunology Branch;   2  Pediatric Oncology Branch, Center for Cancer Research, National 
Cancer Institute;   3  Departments of Radiology;   4  Department of Laboratory Medicine, Clinical Center, National Institutes 
of Health, Bethesda, MD 20892 
  5  Cytheris Inc., Rockville, MD 20850 
  6  Methodist Hospital, Texas Medical Center, Houston, TX 77021 
  7  Biostatistics and Data Management Section, National Cancer Institute,   8  The Cancer Center at Hackensack University Medical 
Center, Hackensack, NJ 07601     
  Interleukin-7 (IL-7) is a homeostatic cytokine for resting T cells with increasing serum and 
tissue levels during T cell depletion. In preclinical studies, IL-7 therapy exerts marked 
stimulating effects on T cell immune reconstitution in mice and primates. First-in-human 
clinical studies of recombinant human IL-7 (rhIL-7) provided the opportunity to investigate 
the effects of IL-7 therapy on lymphocytes in vivo. rhIL-7 induced in vivo T cell cycling, 
bcl-2 up-regulation, and a sustained increase in peripheral blood CD4  +   and CD8  +   T cells. 
This T cell expansion caused a signifi  cant broadening of circulating T cell receptor (TCR) 
repertoire diversity independent of the subjects  ’   age as naive T cells, including recent 
thymic emigrants (RTEs), expanded preferentially, whereas the proportions of regulatory 
T (T reg) cells and senescent CD8  +   effectors diminished. The resulting composition of the 
circulating T cell pool more closely resembled that seen earlier in life. This profi  le, distinc-
tive among cytokines under clinical development, suggests that rhIL-7 therapy could en-
hance and broaden immune responses, particularly in individuals with limited naive T cells 
and diminished TCR repertoire diversity, as occurs after physiological (age), pathological 
(human immunodefi  ciency virus), or iatrogenic (chemotherapy) lymphocyte depletion. 1702 RHIL-7 THERAPY IN HUMANS EXPANDS TCR DIVERSITY   | Sport  è  s et al. 
    Figure 1.         Effects of rhIL-7 therapy on circulating T cells and spleen.   rhIL-7 was administered every other day on day 1  –  14 (8 injections, indi-
cated by tick marks on X axis), at 4 dose levels: 3   μ  g/kg/d (dashed line with    ;   n   = 3); 10   μ  g/kg/d (dotted line with    ;   n   = 3); 30   μ  g/kg/d (dashed line 
with    ;   n   = 5); and 60   μ  g/kg/d (solid line with    ;   n   = 4). Mean value for each cohort (  ±   the SEM) are plotted at the indicated time points. (A) The 
absolute lymphocyte count from complete blood counts (left) and fl  ow cytometry  –  based frequency were used to determine circulating absolute CD3  + /
CD4  +   and CD3  + /CD8 +   counts, absolute numbers   ±   the SEM (bottom graphs), and percent change in absolute numbers over baseline (top graphs) of the 
respective subsets shown on day 1 (total lymphocytes only), 7, 14, 21, and 28 for all treated subjects, as well as day 55  –  90 for subjects treated with 
30 or 60   μ  g/kg/d. Baseline values represent the mean of four separate analyses performed in each subject within 2 wk before initiation of rhIL-7 ther-
apy. (B) Spleen size: bidimensional product by CT scan obtained at the time points shown; percent changes from the pretherapy scan are plotted. 
(C  –  F  )   Baseline (1 value obtained on day 0) and day 7, 14, 21, and 28 data points were generated for CD3  + /CD4 +   (left) and CD3  + /CD8 +   subsets  (right). 
(C) Ki-67 shows the percentage of cells in the respective subsets expressing Ki-67 via fl  ow cytometry at the time points shown. (D) IL-7R     expression JEM VOL. 205, July 7, 2008 
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augments antitumor responses, leading to improved survival 
when combined with antitumor vaccines (  21, 22  ). The capac-
ity for supranormal levels of IL-7 to augment T cell cycling in 
response to antigens with low affi   nity for the TCR appears 
largely responsible for homeostatic peripheral expansion, which 
involves increased T cell proliferation to self-antigens during 
lymphopenia (  13, 23, 24  ). Many studies have documented 
a central role for homeostatic peripheral expansion in the 
immunorestorative eff  ect of IL-7 therapy (  19, 20, 25  ), whereas 
augmentation of thymic output has also been recently sug-
gested (  18  ). In regard to CD4  +  CD25  Hi   regulatory T (T reg) 
cells, IL-2 plays a major role in their development, mainte-
nance, and expansion, whereas T reg cells express low IL-7R     
levels (  26, 27  ) and recent work suggests that IL-7 therapy can 
expand CD4  +   T cells without expanding T reg cells (  28  ). 
  Lymphopenia induced by cytotoxic chemotherapy or other 
insults can signifi  cantly diminish immune function (  29  ). In 
adults, CD4  +   T cell recovery after severe immune depletion re-
quires the reemergence of a pool of naive T cells, which requires 
18  –  24 mo and may occur only in individuals younger than 
40  –  45 yr (  30, 31  ). A therapeutic approach to accelerate, or sim-
ply promote in older individuals, the recovery of a widely di-
verse T cell repertoire may fi  nd a multitude of clinical applications. 
If rhIL-7 therapy in humans can augment immune responses to 
weak antigens, hasten reconstitution of naive T cell populations, 
and spare T reg cell expansion in particular but not restricted to 
older individuals, it could improve the eff  ectiveness of immune-
based therapies for cancer or chronic infection in various popu-
lations with iatrogenic (chemotherapy), pathological (HIV), or 
physiological (aging) immune insuffi   ciency. This study sought to 
characterize the immunobiologic eff  ects of rhIL-7 therapy in 
humans and, specifi  cally, its potential for immune rejuvenation 
of T cell subpopulations. 
    RESULTS   
  IL-7 therapy induces widespread T cell cycling and expands 
the T cell pool in humans in a dose-dependent manner, 
while preserving T cell function 
  To assess eff  ects of IL-7 therapy on human lymphocytes in 
vivo, 16 subjects with refractory cancer (age 20  –  71) were en-
rolled on a phase I dose escalation trial of rhIL-7. Doses ex-
trapolated from mouse and primate studies (3, 10, 30, and 60 
  μ  g/kg) were administered subcutaneously every other day for 
14 d (8 doses). As shown in   Fig. 1 A  , after a very transient de-
crease, circulating numbers of lymphocytes and CD4  +   and 
CD8  +   T cells increased in a dose-dependent manner, with in-
creases at the highest dose level approaching 300% for CD4  +   
and exceeding 400% for CD8  +   T cells.   The initial decrease in 
circulating lymphocytes is likely caused by early traffi   cking out 
of the circulation and is also seen with administration of IL-2 
and, more recently, IL-21. Specifi  cally, we have observed by 
FACS analysis an initial up-regulation of CXCR4 on circulat-
ing lymphocytes with rhIL-7 treatment (unpublished data), 
providing one plausible mechanism for T cell traffi   cking into 
SDF-1  –  rich tissues. 
  The degree of lymphocyte expansion showed no signifi  -
cant relationship to age (Fig. S1 B, available at http://www
.jem.org/cgi/content/full/jem.20071681/DC1) and refl  ected 
increases in total body lymphocytes rather than sole traffi   ck-
ing of lymphocytes from lymphoid tissues into the blood-
stream because they coincided with spleen (  Fig. 1 B  ) and 
lymph node enlargement observed by computerized tomog-
raphy (CT) scan and increased metabolic activity on positron 
emission tomography (PET)-CT on day 14 (  Fig. 2  ).    T cell 
numbers peaked 2 wk after the peak in cycling frequency 
(  Fig. 1, A and C  ), and total lymphocyte numbers remained 
elevated for up to 6 wk after cessation of therapy (  Fig. 1 A  ). 
Additionally, peripheral blood CD3         and CD3  +  /CD16  +   T 
cells increased to a similar extent as          T cells, whereas NK 
cells increased minimally at the two highest dose levels. Cir-
culating B cells decreased during rhIL-7 therapy (Fig. S1 A). 
Pharmacologic serum levels of IL-7 were achieved in a dose-
dependent manner documented on both the fi  rst and last day 
of treatment (Fig. S1 C). The lower serum levels achieved on 
the last day most likely refl  ects the much higher lymphocyte 
mass on that day. 5 out of 15 evaluable subjects developed 
anti  –  rhIL-7 antibodies at day 28 or 35, but importantly, none 
developed neutralizing antibodies as measured in a bioassay 
using an IL-7  –  dependent cell line, and no subject developed 
lymphopenia after treatment. 
  rhIL-7 therapy in primates augmented T cell cycling 
in vivo (  19  ). To evaluate the eff  ects of rhIL-7 therapy on 
T cell cycling in humans, we quantitated Ki-67 expression in 
total circulating CD4  +   and CD8  +   T cells before, during, and 
after IL-7 therapy (  Fig. 1 C  ). At baseline, 1  –  3% of CD4  +   and 
CD8  +   cells expressed Ki-67, but a dose-dependent increase 
in cycling frequency was seen within 7 d of rhIL-7 initiation 
such that   >  40% of CD4  +   T cells and   >  50% of CD8  +   T cells 
expressed Ki-67 in subjects treated at the highest dose level. 
The time course of rhIL-7  ’  s eff  ects on cell cycling was sub-
stantially infl  uenced by dynamic regulation of IL-7R     ex-
pression. Despite continued administration of rhIL-7 through 
day 14 resulting in sustained increases in circulating IL-7 levels 
(Fig. S1 C), T cell cycling substantially declined after day 7 
coincident with IL-7R     down-regulation (  Fig. 1 D  ) that, as 
in mouse models (  7  ), did not simply refl  ect receptor blockade 
or internalization because it was associated with diminished 
mRNA transcription (  Fig. 1 E  ). 
  Like other     c cytokines, IL-7 also supports T cell survival 
by up-regulating members of the antiapoptotic bcl-2 family 
(  32, 33  ), and rhIL-7 therapy induced signifi  cant increases in 
T cell bcl-2 expression in this study (  Fig. 1 F  ); as bcl-2 has 
as MFI via fl  ow cytometry for each subset. (E) IL-7R     mRNA expression represented as mean percent change from baseline of IL-7-R     mRNA  copies 
normalized/10  4   copies of   AXTB   via Q-PCR in sorted CD4  +   and  CD8 +   cells. (F) bcl-2 expression as MFI (after subtracting background staining for each 
subset) via fl  ow cytometry for each subset.     
 1704 RHIL-7 THERAPY IN HUMANS EXPANDS TCR DIVERSITY   | Sport  è  s et al. 
higher than those observed in normal donors or the subjects 
themselves at baseline. Thus, rhIL-7 therapy leads to tran-
sient, widespread T cell cycling that is tightly regulated by 
IL-7R     expression, as well as a more sustained increase in 
bcl-2 expression, resulting in dramatic increases in T cell 
numbers persisting for several weeks after cessation of ther-
apy. These rhIL-7  –  expanded T cells retain robust prolifera-
tive capacity, even to low level of TCR triggering, a fi  nding 
that is consistent with IL-7  ’  s known capacity to costimulate 
TCR signaling and to mediate augmented responses to weak 
antigens (  21  ). 
  Effects of IL-7 versus IL-2 administration in selected T cell 
subpopulations 
  rhIL-2, the only     c cytokine routinely administered thera-
peutically to humans, also increases CD4  +   T cell numbers in 
vivo (  34, 35  ). However, IL-2  –  induced expansion of CD4  +   T 
cell populations in humans involve selective expansion of 
CD4  +  CD25    Hi    ,   FOXP3  +     T reg cells (  34  –  36  ), as predicted by 
the CD25 expression that is the hallmark of this subset. Low 
level IL-7R     expression on T reg cells (  26, 27  ) suggests that 
IL-7 therapy may not selectively expand this subset. To assess 
whether CD4  +   expansion was associated with preferential T 
reg cell expansion,   FOXP3   mRNA was quantifi  ed in sorted 
CD4  +   T cells before and after rhIL-7 therapy (  Fig. 3 B  ). 
  FOXP3   mRNA was not increased in CD4  +   cells collected 
during the period of CD4  +   expansion, nor was any signifi  -
cant   FOXP3   mRNA detected in CD8  +   cells at baseline or 
after therapy. These mRNA data are corroborated by multi-
color fl  ow cytometry analyses performed in selected patients 
from cohort 4, specifi  cally addressing rhIL-7  –  induced prolif-
eration in FOXP3  +   and FOXP3        subsets. In summary, after 
1 wk of treatment with rhIL-7, there is a mean 4.3-fold increase 
of the percentage of CD4  +  /FoxP3  +  /Ki67  +   cells, whereas the 
mean fold increases for CD4  +  /FoxP3       /Ki67  +   cells and for 
CD8  +  /FoxP3       /Ki67  +   cells are 53.4- and 63.9-fold, respec-
tively. After 2 wk of treatment, the mean fold increases are 
1.6-, 24.1-, and 35.7-fold, respectively, whereas at week 3, 1 wk 
after the end of treatment, they are 0.2-, 5.9-, and 9.6-fold. 
Representative two-dimensional plots and overlay histograms 
in one patient are shown in   Fig. 3 C  . 
  Thus, in contrast to rhIL-2, rhIL-7 therapy in humans in-
duces robust CD4  +   T cell expansion without selective ex-
pansion of T reg cells, which is consistent with a recent study 
from a separate cohort of subjects in another clinical trial of 
rhIL-7 (  28  ). Furthermore, multiple studies have also demon-
strated that in vivo IL-2 administration in humans has mini-
mal eff  ects on CD8  +   T cells numbers (  37, 38  ). In contrast, we 
show that the in vivo eff  ects of rhIL-7 on the expansion of 
CD8  +   T cells are, at a minimum, comparable if not superior 
to the eff  ects on CD4  +   T cells. 
  rhIL-7 increases TCR repertoire diversity 
  Because rhIL-7 receptor expression is high on resting, naive 
populations, we postulated that the rhIL-7  –  induced increase 
in circulating T cells could preferentially expand naive cells, 
been well established in animal studies to diminish programmed 
cell death, this rise in bcl-2 expression may have contributed 
mechanistically to the increase in T cell numbers. Whereas 
cell cycling rates were tightly linked to IL-7R     expression, 
bcl-2 up-regulation was sustained throughout therapy. At 
higher dose levels, bcl-2 expression persisted above baseline 
for at least 1 wk after discontinuation of rhIL-7 therapy. This 
sustained increase in bcl-2 expression was likely to be physi-
ologically signifi   cant and contributed to the sustained in-
creases in lymphocyte number observed, as similar eff  ects 
have been seen in animals when sustained bcl-2 expression 
is induced. 
  To assess functionality of rhIL-7  –  expanded T cells, pro-
liferation in response to TCR signaling in vitro was measured 
using titrated doses of plate-bound anti-CD3 (  Fig. 3 A  ).   
rhIL-7 therapy substantially increased maximal T cell prolif-
eration, which peaked on day 14, the last day of therapy. 
Proliferative responses to fully mitogenic doses of anti-CD3 
were approximately threefold greater than at baseline and, at 
very low doses of anti-CD3 stimulation, rhIL-7  –  treated sub-
jects showed increases in proliferation greater than one log 
    Figure 2.     PET-CT imaging of the self-limited lymphoid organs  ’   
enlargement and increased metabolic activity after rhIL-7 therapy.  
Shown are representative images on PET-CT scan in one subject (42-yr-
old female treated with 60   μ  g/kg/dose). (left) Imaging on day 14 (last day 
of rhIL-7 treatment). (right) Day 56 (6 wk after the end of treatment). The 
full ovals indicate areas of increased size (except for vertebral bodies) 
and activity of lymphoid organs (left and right axillary adenopathy, 
spleen, and lumbar spine) at the end of treatment. The dotted contours 
indicate the thymic area where no increased activity can be demonstrated 
at day 14. Increased metabolic activity is seen in pink and maximal in 
yellow  areas.   JEM VOL. 205, July 7, 2008 
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the pre- and post-therapy spectratype divergence from a nor-
mal donor standard was assessed (see Materials and methods). 
Indeed, 4 of the 6 subjects tested had a statistically signifi  cant 
increase in repertoire diversity by 1 wk after the end of treatment 
and therefore lead to an overall increase in TCR diversity. 
TCR diversity spectratype analysis was performed on sorted 
CD4  +   and CD8  +   populations before and after (day 21) rhIL-7 
therapy in 6 subjects treated at either 30 or 60   μ  g/kg, and 
    Figure 3.     rhIL-7  –  expanded T cells show robust proliferative responses to CD3 signaling and are not enriched for   FOXP3   expressing cells.      
(A) PBMCs were collected at the time points shown, cryopreserved, and then thawed before analysis. Proliferation in response to titrated doses of plate-
bound anti-CD3 was measured by   3  H incorporation, as described in the Materials and methods. Similar increases in CD3-induced proliferation were ob-
served across dose levels, therefore results for all dose levels are pooled (  n   = 15) and compared with normal donors run simultaneously (solid line with    , 
  n   = 16). rhIL-7  –  treated subjects showed increased proliferative responses to anti-CD3 on day 7 (dotted line with     ), day 14 (dashed line with     ), and day 
21 (dashed line with     ) compared with normal donors and on day 7 and 14 compared with baseline values (dashed and dotted line with fi  lled   	 ;  P   <  
0.05, two-tailed Mann-Whitney test). (B)   FOXP3   mRNA copies per 10  4    AXTB   mRNA were quantifi  ed from sorted CD3  + /CD4 +   cells as detailed in the Mate-
rials and methods. No signifi  cant change in   FOXP3   mRNA was detected between baseline values (white) and values obtained at the time of CD4  +   expan-
sion (day 14 in gray and day 21 in black; P = NS). Mean   ±   the SEM of data from subjects enrolled at each dose level are shown: 3   μ  g/kg (  n   = 2), 10   μ  g/kg 
(  n   = 3), 30   μ  g/kg (  n   = 4), and 60   μ  g/kg (  n   = 5). (C) Two-dimensional plots (top) and overlay histograms (bottom) of Ki67 expression in T reg cells and other 
CD4  +   and CD8  +   T cells in an individual subject. Percent Ki-67  +   cells are indicated in each frame. Pretreatment, shaded histograms; day 7, black; day 14, 
dark gray; day 21, light gray.     1706 RHIL-7 THERAPY IN HUMANS EXPANDS TCR DIVERSITY   | Sport  è  s et al. 
    Figure 4.     rhIL-7 therapy increases TCR repertoire diversity by V     family spectratype analysis.   (A) Schematic representation of the methodology. 
V     family spectratype analysis was performed for each of 6 subjects (3 of each cohort 3 and 4), separately on CD4  +   and  CD8 +   cells by RT-PCR on RNA 
extracted from sorted T cells at baseline and at D21. The distributions of peaks for each V     family are graphically represented on a curve. (B) Schematic of 
divergence score calculation. Divergence from the normal donor standard was calculated for each V     family, separately for CD4  +   and  CD8 +   cells, for each 
individual, at baseline and at day 21. Two V     families  (V   14 on the left and V    23 on the right) are illustrated for the sorted CD8  +   population in one indi-
vidual (Pt 11), pre (rows 1 and 3), and post (rows 2 and 4) therapy. Overlays of histograms for the subject (no color) and the normal donor standard (in 
gray) illustrate how the divergence scores were calculated (see Materials and methods). (C)     Divergence scores for CD8  +   cells in one subject. Divergence 
scores are shown at baseline (pre) and day 21 (post) for each V     family, and a diversity shift was obtained (Pre-Post). The median diversity shift (a positive 
value indicates a shift toward greater repertoire diversity) and the P value of Wilcoxon pair test comparing the pre and post divergence scores are shown, JEM VOL. 205, July 7, 2008 
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(day 21) compared with baseline in CD4  +  , CD8  +  , or both 
T cell populations (  Fig. 4  ).   The two other subjects showed a 
strong trend in at least one population. Such changes are sur-
prising given the short time period that had elapsed since 
beginning rhIL-7 therapy, as eliciting spectratype profi  le dif-
ferences would be diffi   cult both in the case of individuals 
with an initially very diverse repertoire (hence, with little 
possibility of improvement) and of those with a severely de-
pleted repertoire (with marked divergence from a normal 
donor standard). 
  rhIL-7 therapy selectively expands CD4  +   recent thymic 
emigrants (RTEs), naive cells, and central memory 
populations, but not effector T cells 
  IL-7R     expression is tightly regulated during postthymic 
T cell differentiation, such that RTEs (  25, 39  ), naive, and 
early memory populations (  40  ) express high IL-7R     levels, 
whereas eff  ectors and late memory/senescent populations ex-
press lower levels (  41, 42  ). To determine whether the eff  ects 
of rhIL-7 therapy on TCR repertoire diversity could be ex-
plained by varied eff  ects among peripheral T cell subsets with 
diff  erential IL-7R     expression, we measured cycling rates, 
bcl-2 expression, peripheral blood frequencies, and absolute 
numbers of RTEs, naive, eff  ector, and memory populations 
before, during, and after therapy.   Fig. 5   illustrates representa-
tive changes in a single subject (treated at 60   μ  g/kg),   Fig. 6   
summarizes fi  ndings across subjects and dose levels; detailed 
kinetics for all subsets are included in Fig. S2 (available at 
http://www.jem.org/cgi/content/full/jem.20071681/DC1).    
  Using CD45RA with CD27 or CCR7 coexpression to de-
fi  ne the naive subsets, rhIL-7 therapy preferentially expanded 
naive CD4  +   and CD8  +   T cells, leading to increased frequency 
(  Fig. 5, A and C  ) and absolute numbers (  Fig. 6, A and D  ). 
Similarly, CD4  +   RTEs defi  ned by coexpression of CD45RA 
and CD31 substantially increased both in frequency and 
number after rhIL-7 therapy. In addition, modest expansion 
of the memory and eff  ector subsets were observed (  Fig. 6 A  ), 
which appeared to preferentially involve CD4  +   central mem-
ory cells (  Fig. 6 D  ). Of all subsets, the naive CD8  +   expanded 
the most and signifi  cantly more than the CD8  +   memory and 
eff  ector subsets (P = 0.008), and these eff  ects were similar re-
gardless of subject age (Fig. S1 B). This preferential eff  ect on 
naive cells, including RTEs, was not caused by diff  erences in 
maximal Ki67 expression because rhIL-7 similarly increased 
the cycling rate of nearly all subsets in a steep dose-dependent 
manner (  Fig. 5 B and Fig. 6 B  ) by day 7 of therapy, followed 
by a gradual return to near baseline by day 21 (  Fig. 5 B   and 
Fig. S2). Interestingly, however, whereas memory and eff  ector 
subsets showed a brisk decline in Ki67 frequency by day 14, 
there remained a distinct subset of Ki67  +   cells at this time 
point in both CD4  +   and CD8  +   naive subsets (  Fig. 5 B  ). rhIL-7 
also induced a dose-dependent increase in bcl-2 mean fl  uo-
rescence intensity (MFI) in all subsets except CD8  +   eff  ectors 
(  Fig. 6 C  ). Thus, rhIL-7 therapy increased total body T cell 
mass with preferential expansion of the naive subsets, result-
ing in a T cell pool in this adult population that more closely 
resembles that seen earlier in life. This could potentially relate 
to fi  ne diff  erential kinetics of cell cycling, IL-7R     expression, 
or bcl-2 up-regulation, although changes in these parameters 
of similar magnitude were observed in nonnaive subsets as 
well (Fig. S2). Alternatively, these results could suggest that, 
after similar levels of rhIL-7 signaling, naive T cells undergo 
a greater proliferative burst than memory or eff  ector subsets 
and/or that some component of the increase in naive subsets 
refl  ects input of cells from an alternative source. 
  rhIL-7 increases circulating TCR excision circles (TRECs) 
numbers 
  Because rhIL-7 preferentially increases RTEs and naive T 
cells, we investigated a potential thymic contribution to its 
eff  ects. Peripheral blood TRECs have been used as an in-
direct measure of thymic output because they refl  ect TCR 
gene recombination events and are enriched within the 
RTE fraction ( 43  ). Because TRECs are nonreplicating DNA, 
however, they become diluted with T cell division and, in 
preclinical primate studies (  19, 20  ), TREC frequencies di-
minished after rhIL-7 therapy, presumably caused by induced 
cycling in RTEs (  44  ). In this study, we observed diminished 
absolute numbers of circulating TRECs/milliliter on day 7 
(  Fig. 7 A  ), an expected refl  ection of the diminished total 
number of circulating phenotypically naive cells at that point, 
followed by an increase in the absolute number of TRECs/
millimeter  3   (doubling in the 2 highest dose cohorts) between 
days 7 and 21, which is consistent with the subsequent rise in 
naive T cell absolute number.   Despite widespread rhIL-7  – 
induced T cell cycling, TREC  +   frequencies were largely un-
changed in sorted CD4  +   and CD8  +   peripheral T cells before 
and after therapy (  Fig. 7 B  ). The absence of profound reduc-
tions in TREC frequencies in the face of signifi  cant T cell 
cycling raises the possibility that rhIL-7 might also induce 
new thymic emigrants to enter the circulation. However, in 
other clinical settings such as after chemotherapy, where a 
substantial thymic output increase does occur, it occurs later, 
is preceded by a thymic size increase on CT scan, is accom-
panied by a   >  10-fold increase in TREC, and the magnitude 
of the eff  ects diminishes with increasing age (  30, 45  ). We ob-
served no increase in thymic size on day 14 or 28 CT scans 
after rhIL-7 therapy, and there was not a signifi  cant correlation 
and then incorporated into the summary in D. (D) Summary of repertoire diversity analysis. for each tested individual (age), shown at baseline (D0) and 
D21 are as follows: the total naive CD4  +   and naive CD8  +   cells counts; the median diversity shift for each CD4 and CD8 subsets of each individual and the 
P values of the Wilcoxon pair test indicating the likelihood that the calculated change in divergence scores for a particular subject ’ s  CD4 +   or  CD8 +   cells 
between day 21 and baseline occurred by chance; P values   <  0.05 indicate a statistically signifi  cant increase in diversity toward normality between baseline 
and day 21 studies.     
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    Figure 5.         rhIL-7 therapy induces cycling of most T cell subsets, but preferentially expands naive CD4  +   and CD8  +   cells and CD4  +   central 
memory cells.   Representative data from a single subject treated at 60   μ  g/kg/d are shown. (A) Two-dimensional plots illustrating the rhIL-7 therapy  – 
induced increased frequency of CD4  +   RTEs  (CD31 + /CD45RA +  ; red boxes in fi  rst row of graphs), and changes in CD4  +   and  CD8 +   naive, memory, and effector 
subsets (respectively CD45RA  + /CD27 + ,  CD45RA     /CD27 +  , and CD45RA      /CD27       sections on second and third rows). (B) Overlay histograms of Ki-67 ex-
pression on CD4  +   RTEs  (CD31 + /CD45RA + )  and  CD4 +   and  CD8 +   naive  (CD45RA + /CD27 +  ), memory (CD45RA      /CD27 +  ), and effector (CD45RA      /CD27     ) 
subsets. Percent Ki-67  +   cells are indicated in each frame. Red lines, pretreatment; blue lines, day 7; green lines, day 14; orange lines, day 21. Note that at JEM VOL. 205, July 7, 2008 
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between age and TREC increase (Fig. S1 B). We also per-
formed a similar TREC analysis on sorted naive CD4  +  /CD31  +  /
CD45RA  +   cells and naive CD8  +  /CD27  +  /CD45RA  +   cells 
before and after rhIL-7 therapy to probe for increased cycling 
of this subset resulting in TREC dilution. Indeed, in the two 
individuals studied, we observed pronounced dilution of 
TRECs (reduction by 80 and 62% of TRECs/200K RNaseP 
copies in sorted CD4  +   RTEs, and reduction by 32 and 56% 
of TRECs/200K RNaseP copies in sorted CD8  +   naive T cells) 
after rhIL-7 therapy, which is consistent with intense prolif-
eration in these subsets. Therefore, although rhIL-7  –  induced 
augmentation of thymopoiesis cannot be ruled out, the avail-
able data are most consistent with rhIL-7  –  induced entry of 
new thymic emigrants into the circulation via mobiliza-
tion from lymphoid sites and/or enhanced thymic egress, as 
previously observed in an animal model of IL-7 adminis-
tration (  25  ), in concert with vigorous cycling of the naive 
and RTE subsets. 
  In summary, rhIL-7 induces increases in total body T cell 
mass accompanied by an age-independent overall increase in 
TCR repertoire diversity. Preferential expansion of naive 
subsets leads to an increased TCR diversity and changes in 
peripheral T cell subset compositions that reverse the aged 
phenotype. The timing of this increase, the lack of frank in-
crease in the absolute number of circulating TRECs, the 
marked dilution eff  ect on TRECs in the naive subsets of se-
lected individuals, and the detailed phenotypic analysis of 
T cells subset kinetics indicate that this increase in TCR diver-
sity primarily arises from the preferential peripheral expansion 
of the RTEs and naive T cells, the most diverse components 
of the T cell pool. 
    DISCUSSION   
  Administration of supraphysiologic doses of recombinant 
growth factors to augment hematopoietic cell recovery has 
had a substantial impact in medical practice, with recombi-
nant proteins now available to enhance red cell, white cell, 
and platelet regeneration approved for clinical use. Thus far, 
however, no agent able to safely expand a broad repertoire of 
T cells has been identifi  ed, and impaired immune reconstitu-
tion remains problematic in many clinical settings (  46  ). Several 
preclinical studies have implicated IL-7 as a primary modula-
tor of peripheral T cell homeostasis with potent immuno-
restorative properties, raising the prospect that rhIL-7 may 
serve as a clinically eff  ective T cell growth factor. This study 
demonstrates that rhIL-7 administration in humans can safely 
induce polyclonal T cell expansion in vivo, resulting in dra-
matic increases in T cell number. Although the clinical details 
associated with the therapy are the focus of a separate report 
(unpublished data), the agent was well tolerated on this trial. 
Mechanistically, the eff  ect of rhIL-7 can be attributed to a 
combination of increased cell cycling, likely via TCR trig-
gering to cross-reactive self-antigens, and diminished pro-
grammed cell death, which was self-limited by down-regulation 
of IL-7R     in the face of continued drug administration. The 
rhIL-7  –  expanded T cells remained functional, retaining robust 
responsiveness to TCR triggering with even a suggestion of 
increased sensitivity to TCR ligation after a suboptimal stimulus, 
as seen in preclinical models. 
  rhIL-7 preferentially expanded naive CD4  +   and CD8  +   
subsets, including the most naive circulating RTEs (CD4  +  /
CD45RA  +  /CD31  +  ), consistent with the results from mouse 
studies (  44  ). The eff  ects on CD4  +   and CD8  +   memory cells 
and CD4  +   eff  ectors were intermediate, whereas CD8  +   ef-
fectors underwent little expansion. Notably, rhIL-7  –  expanded 
central memory CD4  +   T cells, a subset that may be criti-
cally important in avoiding clonal exhaustion in the con-
text of chronic persistent viral or tumoral antigenic exposure 
(  47, 48  ). It is also noteworthy that rhIL-7 preferentially 
expanded the two subsets of T cells capable of initiating 
lymph node germinal center formation, the naive and cen-
tral memory subsets. 
  Despite the clear evidence presented in this study that 
rhIL-7 therapy substantially increases TCR diversity by an 
increase in the size of the naive T cell pool, the contribution 
of the thymus to these rapid changes remains unclear. Pre-
clinical studies provide evidence both for and against rhIL-7  –
  induced augmentation of thymopoiesis (  18  –  20  ). In this study, 
we observed increases in absolute numbers of TRECs (albeit 
modest) and in numbers of peripheral blood phenotypic 
RTEs. However, we saw neither evidence for thymic en-
largement nor signifi  cant correlation between age and rhIL-7 
eff  ects. Furthermore, our TREC analysis on sorted naive 
CD4  +  /CD31  +  /CD45RA  +   cells and naive CD8  +  /CD27  +  /
CD45RA  +   cells shows a pronounced dilution eff  ect  of 
TRECs consistent with the intense proliferation in these subsets, 
thus arguing that the observed eff  ect on repertoire diversity is 
in large part caused by decreased skewing by proliferation 
of RTEs. Together, these data suggest that the observed 
changes refl  ected rhIL-7  –  induced increases in RTE cycling, 
as well as traffi   cking of RTEs from peripheral lymphoid tis-
sue into the bloodstream as seen in the mouse model (  25, 44  ), 
whereas no direct eff  ect on thymopoiesis can be demon-
strated in the short time span of this study. Indeed, in clinical 
settings, thymic participation in immune reconstitution in 
adults is delayed for several months after the depleting event 
(  30  ), raising the possibility that more direct thymopoietic ef-
fects of rhIL-7, if induced, could require more chronic rhIL-7 
administration. However, even if the observed rhIL-7 eff  ects 
are thymic independent and refl  ect naive cell expansion 
rather than increased thymic throughput per se, the net eff  ect 
of rhIL-7 therapy remains a substantial, measured, increase in 
the end of treatment (green line), the percentage of Ki67  +   memory and effector CD8  +   populations drop to lower levels than the naive CD8  +  . (C) Two-
dimensional plots illustrating the rhIL-7 therapy  –  induced changes in CD4  +   (top row) and CD8  +   (bottom row) naive, central memory, effector memory, 
and effectors (respectively CD45RA  + /CCR7 + ,  CD45RA     /CCR7 + ,  CD45RA     /CCR7      , and CD45RA  +/    /CCR7       sections).   
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TCR repertoire diversity in adult subjects, thereby reshaping 
their T cell pool. During the aging process, the accumulation 
of senescent and more oligoclonal CD8  +   cells with a terminal 
diff  erentiation phenotype has been associated with dysfunc-
tional immune responses (  49  ). The eff  ects of rhIL-7 on naive 
and central memory subsets could restore balance in T cell 
subsets during immunological aging and restore a T cell pro-
fi  le resembling that seen earlier in life. Such   “  antiaging  ”   ef-
fects could prove benefi  cial for T cell  –  depleted hosts or older 
hosts, where the combined loss of total T cell number, naive 
cells, and the corollary loss of repertoire diversity appears to 
contribute to diminished overall immune responsiveness. 
  In summary, in this fi  rst clinical trial of rhIL-7 initiated in 
humans, and after the brief study of another National Cancer 
Institute  –  initiated trial (  28  ), we present evidence that rhIL-7 
therapy in humans induces dramatic, polyclonal, prolonged 
CD4  +   and CD8  +   T cell expansion in vivo, with preferential in-
creases in T cells bearing diverse TCR repertoire specifi  cities. 
The eff  ects are mediated primarily through increased peripheral 
T cell cycling and augmented cell survival. The rhIL-7  –  ex-
panded T cells retain signifi  cant functional capacity, and the 
CD4  +   T cell expansion is not accompanied by a disproportional 
increase in T reg cells, such as that which occurs after rhIL-2 
therapy. rhIL-7 appears to be an eff  ective T cell growth factor 
    Figure 6.         rhIL-7 induces cycling and increases bcl-2 expression 
across subsets, but preferentially expands naive T cells and CD4  +   
memory cells  . Changes in cell number (A), Ki-67 expression (B), and bcl-2 
expression (C) are shown for subjects treated at 3   μ  g/kg/d (white), 10   μ  g/
kg/d (speckled), 30   μ  g/kg/d (gray), and 60   μ  g/kg/d (black). The time points 
shown represent the point of maximal increase for each parameter, as 
illustrated in   Fig. 1  , as follows: day 21 for increase in cell number, day 7 
for Ki-67, and day 14 for bcl-2 expression. (A) Percent increase in absolute 
circulating cell number (per milliliter) over pretherapy value for each sub-
set at day 21 after rhIL-7. Percent increase in the naive CD8  +   subset  were 
signifi  cantly higher than for the CD8  +   memory (P = 0.008) or CD8  +   effec-
tor subsets (P = 0.008). (B) Net increase in the proportion of Ki67  +   cells  in 
each subset at day 7 was calculated by subtracting the percentage of 
each subset that expressed Ki-67 at baseline from the percentage ex-
pressing Ki-67 at day 7 of rhIL-7 therapy. (C) Net increase in bcl-2 MFI in 
each subset at day 14 was calculated by subtracting the MFI of bcl-2 
expression at baseline from the MFI on day 14 after rhIL-7 for each sub-
set. See Fig. S2 for detailed data on changes in subset parameters for each 
dose level. (D) Net increase in cell number at day 21 in subsets defi  ned by 
CCR7 and CD45RA surface expression (see Materials and methods) as 
follows: naive (CCR7  + CD45RA +  ), central memory (CCR7  + CD45RA     ),  effec-
tor memory (CCR7      CD45RA      ), and effector RA (CCR7      CD45RA + ).  Mean 
value for the six studied subjects. Error bars represent the SEM. Fig S2 is 
available at http://www.jem.org/cgi/content/full/jem.20071681/DC1.     
    Figure 7.     rhIL-7 therapy increases the number of TREC-expressing 
cells in the peripheral blood.   We measured TRECs in sorted CD4  +   and 
CD8  +   T cells at the time points shown, and values shown were normalized 
per 10  5   cells. Individual subjects (    ); mean of cohort (  ±   the SEM): 3   μ  g/
kg/d (dashed line with     ), 10   μ  g/kg/d (dotted line with     ), 30   μ  g/kg/d 
(dashed line with     ), 60   μ  g/kg/d (solid line with     ). Tick marks represent 
rhIL-7 injections. (A) Absolute number of circulating TRECs/mm  3   of  blood 
diminished during the fi  rst 7 d of rhIL-7 therapy, consistent with a de-
crease in naive populations during this period. Rises in TRECs were ob-
served from day 7  –  28, consistent with increased numbers of enumerated 
phenotypically naive cells during this period. (B) No signifi  cant changes in 
the frequency of TRECs/10  5   sorted total CD4  +   or  CD8 +   cells was observed, 
despite increases in cell cycling shown in   Figs. 1 and 6   (see text for TRECs 
in naive subsets).     JEM VOL. 205, July 7, 2008 
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We stained cells with CD8-Pacifi  c Blue, CD3-APC-Cy5.5, CD45RA-PECy5 
(all Invitrogen), CD27-APC (eBioscience), CD4-APC-Cy7, and CD31-
FITC (all BD Biosciences); fi  xed; permeabilized (BD Biosciences); stained 
for intracellular markers with isotype control-PE, Ki-67-PE or Bcl-2-PE (all 
BD Biosciences); and analyzed on a LSR II fl  ow cytometer (BD Biosciences) 
equipped with violet 405, argon 488, and HeNe 635 lasers. We acquired 
data using DIVA software (BD Biosciences) and analyzed using FlowJo 
(Tree Star, Inc.). Gating on populations of CD3  +  CD8  +   and CD3  +  CD4  +   T 
cells, expression of Ki67 or bcl-2 was determined on T cell subsets defi  ned 
by the following antibody expression patterns: RTEs as CD4  +  /CD45RA  +  /
CD31  +  , naive CD4 or CD8 T cells as CD27  +   CD45RA  +  , memory as 
CD27  +  CD45RA    –   , and eff  ector T cells as CD27    –    CD45RA  +/     . Alternatively, 
cells were stained with CCR7-FITC (R  &  D Systems), and the remaining 
surface markers and analyzed for naive (CCR7  +  CD45RA  +  ), central memory 
(CCR7  +  CD45RA    –   ), eff  ector memory (CCR7    –   CD45RA    –   ), and eff  ector 
RA (CCR7    –   CD45RA  +  ), following the research of Sallusto et al. (  50  ). We 
calculated the absolute cells number/milliliter expressing a particular pheno-
type by multiplying the frequency of the subset within CD4 or CD8 T cells 
by the absolute number of those cells as calculated during cytometric analysis 
of fresh whole blood. 
  IL-7RA    ,   FOXP3   message determination 
  We used electronically sorted CD4  +   and CD8  +   populations for RNA ex-
traction. We extracted RNA using Trizol (Invitrogen) according to the 
manufacturer  ’  s instructions, and then reverse transcribed 500 ng of RNA 
using the SuperScript III First-Strand Synthesis System (Invitrogen). We 
performed quantitative PCR using the Taqman ABI Prism 7000 Sequence 
Detection System (Applied Biosystems) on cDNA samples for   FOXP3   and 
  IL-7RA   expression, and normalized them to the housekeeping gene   ACTB  . 
We purchased probes for detection of   FOXP3  ,   IL-7RA  ,   ACTB  , and the 
Taqman Universal PCR Master Mix (Applied Biosystems) and used them 
according to the provided protocol. We generated standard curves to quan-
tify   FOXP3  ,   IL-7RA  , and   ACTB   by cloning   FOXP3  ,   IL-7RA  , and   ACTB   
PCR products into plasmids using Platinum Taq and TOPO TA Cloning 
kit (Invitrogen) as per the manufacturer  ’  s instructions. PCR conditions 
were a 94  °  C 2-min hot start followed by 94  °  C for 30 s, 58  °  C for 30 s, 
72  °  C for 45 s for 30 cycles, and culminating in a fi  nal 72  °  C 7-min extension 
step. Primer sequences were as follows:   ACTB  , 5    -GAGCACAGAGCC-
TCG  C  C  TTTG-3     (sense), 5    -CGCCCACATAGGAATCCTTCT-3     
(antisense);   FOXP3  , 5    -GCACCTTCCCAAATCCCAGT-3     (sense), 
5    -GCAG      GCAAGACAGTGGAAACC-3     (antisense);   IL-7RA   proprietary 
(  “  HS00233682  ”   from ABI). 
  T cell proliferation in response to anti-CD3 signaling 
  We thawed PBMC cryopreserved at each time point, and then incubated it 
for 2 d in 200   μ  l/well of 10% human AB serum/AIM-V medium on 96-well 
fl   at-bottomed plates (Nunc) coated with the designed concentrations of 
OKT3 (Orthoclone). We measured cell proliferation by incorporation of 
[  3  H]thymidine (1     Ci/well; ICN) after a 16  –  18-h pulse. Cpm refl  ects pro-
liferation after anti-CD3 minus cell proliferation in the medium. We ran 
normal donor controls with each assay. 
  TREC analysis 
  For TREC analysis, we sorted CD3  +  CD4  +   and CD3  +  CD8  +   T cells and, in 
two subjects, CD4  +  /CD31  +   and CD8  +  /CD45RA  +   T cells from cryopreserved 
PBMC on a FACSVantage (D Biosciences). Real-time quantitative-PCR was 
performed using the 5    -nuclease (Taqman) assay on cell lysates on an ABI7700 
system (Applied Biosystems) according to the protocol of Douek et al. (  43  ). 
Cells were lysed in 100   μ  g/ml proteinase K (Boehringer-Mannheim) in 10 
mM TRIS, and heated for 1 h at 56  °  C, and then for 10 min at 95  °  C. PCR 
reactions contained Platinum Quantitative PCR SuperMix-UDG with ROX 
(Invitrogen) with 500 nM of each primer, and 150 nM probe. PCR conditions 
were 95  °  C for 5 min, 95  °  C for 30 s, and 60  °  C for 1 min for 40 cycles. The 
forward and reverse TREC primers were 5    -CACATCCCTTTCAACCAT-
GCT-3     and 5    -GCCAGCTGCAGGGTTTAGTG-3    , respectively, and 
with   “  immune rejuvenating  ”   properties that suggest it would 
be eff  ective in augmenting immune reactivity in hosts with 
impaired immunity caused by physiological (age), iatrogenic 
(chemotherapy/transplantation), or pathological (HIV) lym-
phodepletion. In immunologically normal, as well as defi  cient 
hosts, rhIL-7  ’  s capacity to augment responses to weak antigens 
and to increase T cell cycling without T reg cell expansion 
may be clinically exploitable in the context of immunotherapy 
regimens for cancer and/or chronic infection. Future clinical 
studies of rhIL-7 in the context of immune-based therapies 
are warranted. 
    MATERIALS AND METHODS   
  Subject population and trial design 
  We enrolled 16 subjects with nonhematologic, nonlymphoid cancer refrac-
tory to standard therapy on a standard phase I dose escalation study of rhIL-7 
(National Cancer Institute, NCI protocol 03-C-0152). The study was ap-
proved by the Institutional Review Board of the NCI and by the Food and 
Drug Administration. All subjects signed a written informed consent before 
enrollment. Subjects received subcutaneous injections of rhIL-7 (provided 
by Cytheris Inc., Rockville, MD) at the doses noted every other day for 
eight doses. A maximum tolerated dose was not reached on this study, and 
two subjects experienced dose limiting toxicity. One patient treated at 30 
  μ  g/kg/d received only one injection before being removed from the study 
(because of a grade 3 transaminase elevation) and is not included in the ana-
lyses. Another subject was removed from study (because of grade 3 hyper-
tension and chest pain) after receiving the fi  rst four injections at 60   μ  g/kg/d 
and is included in the relevant analyses. Signifi  cant diff  erences in the pattern 
of total lymphocyte expansion were not seen when this subject was com-
pared with the study subjects who completed the treatment. A detailed de-
scription of the eligibility criteria, subject population, and clinical results of 
this trial is the object of a separate report (unpublished data). 
  Flow cytometry and cell sorting 
  PBMC analysis.     We used fl  ow cytometry to assess the intracellular and cell 
surface expression of selected markers on PBMCs at the specifi  ed  time 
points. We analyzed EDTA anticoagulated peripheral blood specimens on 
the same day without cryopreservation; the specimens were handled accord-
ing to established clinical guidelines. We stained 3 ml of the samples for 4-
color fl  ow cytometry using a whole-blood lysis method; the samples were 
analyzed on a FACSCalibur (BD Biosciences) using CellQuest software (BD 
Biosciences). We used an additional 5 ml of blood to generate mononuclear 
cells via density gradient separation for determination of intracellular Ki-67 
expression in T cells and T cell subsets. We identifi  ed T cells and T cell sub-
sets using directly conjugated monoclonal antibodies: anti-CD3, -CD4, 
-CD8, -    /     TCR, and -    /     TCR; T cells were further characterized using 
anti-CD9, -CD11a, -CD71, -CD127, -CD184, and -Ki-67. We evaluated 
B cells with anti-CD20 and NK cells with a combination of anti-CD16 and 
-CD56, evaluated on CD3       lymphocytes. We used directly conjugated, 
mouse IgG1 to ascertain background staining. We identifi  ed lymphocytes 
based on a gate established by forward and side-angle scatter, and confi  rmed 
using anti-CD45/-CD14 (Leukogate; BD Biosciences). The absolute num-
ber for each population was generated using absolute peripheral blood lym-
phocyte count, determined by a Cell Dyne Sapphire (Abbott). We used 
peripheral blood from healthy adult controls to establish 95% confi  dence in-
tervals. We obtained all monoclonal antibodies from BD Biosciences, with 
the exception of anti-CD4, -CD8, -CD127, and -    /     TCR (Beckman 
Coulter), anti-    /     TCR (Pierce-Endogen), and anti-CD11a (Dako). 
  CD4  +   and CD8  +   T cell subset analysis 
  We further analyzed cryopreserved PBMC to examine T cell subsets, markers 
of cell proliferation and apoptotic susceptibility within these subpopulations. 1712 RHIL-7 THERAPY IN HUMANS EXPANDS TCR DIVERSITY   | Sport  è  s et al. 
when comparing two groups was determined by two-tailed unpaired nonpara-
metric Mann-Whitney test. P values were considered signifi  cant if   <  0.05. 
  Correlation with age.     We evaluated the statistical signifi  cance of the cor-
relation of age with the percent increase of various lymphocyte populations, 
as well as with TRECs, with a Spearman  ’  s correlation test with a signifi  cant 
2-tailed P value of   <  0.05 (GraphPad Prism version 4.0a for Macintosh; 
GraphPad Software). 
  Spectratyping analysis.     See previous section. 
  Online supplemental material 
  Fig. S1 shows time courses of various lymphocyte populations following 
rhIL-7 therapy. Fig. S2 shows time course on percent change over baseline 
in circulating cells, Ki67 expression, and Bcl-2 up-regulation for all studied 
subsets. The online version of this article is available at http://www.jem
.org/cgi/content/full/jem.20071681/DC1. 
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the probe FAM-5    -ACACCTCTGGTTTTTGTAAAGGTGCCCACT-
TAMRA (Integrated DNA Technologies, Inc.). A standard curve (10  2  –  7   
TREC copies/well) was plotted using a plasmid containing the TREC gene 
sequence (provided by D.C. Douek, National Institutes of Health, Bethesda, 
MD). We normalized TREC values to cell content by concurrent measure-
ment of the single-copy gene, RNase P, using the TaqMan RNase P Control 
Reagents kit (Applied Biosystems). Samples were analyzed in duplicate, and 
the results were averaged and normalized as TRECs/200,000 copies RNaseP, 
equaling TRECs/100,000 cells. 
  T cell repertoire diversity evaluation and statistical evaluation of 
TCR     -chain variable region (V    ) spectratypes 
  We performed spectratype analyses separately on CD4  +   and CD8  +   T cell 
subsets from 6 subjects (3 each of cohorts 3 and 4). We sorted CD3  +  CD4  +   
and CD3  +  CD8  +   T cells to 98% purity from cryopreserved PBMC on a FACS 
Vantage (BDIS). We used 10  5   cells of each to isolate RNA using Trizol (In-
vitrogen) in the presence of carrier tRNA and glycogen as carrier, and con-
verted to cDNA using Oligo-dT as a primer for reverse transcription (First 
Strand cDNA kit; Roche). We amplifi  ed cDNA in 22 separate PCR reac-
tions (V     families 1  –  24, excluding V     10 and 19), each containing 1 specifi  c 
human V     subfamily primer coupled with an unlabeled consensus C     region 
primer, followed by a 10-cycle run-off   nested PCR reaction, using a FAM-
labeled internal BC primer (Integrated DNA Technologies, Inc.). Labeled 
run-off   reaction C     primer and V     family-specifi  c (forward) primers were as 
specifi  ed in Currier et al. (  51  ), except for V     5, 13, 15, and 16. These re-
maining V     primers and the C     primer were as from Puisieux et al. (  52  ). The 
initial and run-off   PCR used 0.75 U cloned PFU DNA polymerase (Strata-
gene), and PCR settings were hot start with 2 min at 95  °  C followed by 30 
cycles of 95  °  C for 30 s, 55  °  C for 45 s, and 72  °  C for 1 min, followed a fi  nal 
extension at 72  °  C for 10 min. Run-off   reaction product was mixed at 1:9 ra-
tio with loading buff  er, consisting of Hi-Di Formamide (Applied Biosystems) 
containing size standards GeneScan-500 ROX, Red A (Applied Biosystems) 
mixed at a 1:20 ratio. Reactions were heated for 2 min at 95  °  C, and products 
were run on an ABI sequencer 3130XI (Applied Biosciences). Peaks were 
identifi  ed in the fi  nal spectratype histogram, and the area underneath was de-
termined using GeneMapper v. 3.7 software (Applied Biosciences). 
  Using this same methodology, we also analyzed each V     family of 10  –
  15 normal donor T cells (CD4  +   and CD8  +   combined), thereby defi  ning 
  “  normal donor standards.  ”   For each donor  ’  s spectratype, we aligned the 
peaks by nucleotide base pair number, and used the area under each of 13 
potential peak locations to calculate a total area under the spectratype curve, 
and then a proportional area for each peak. We then averaged the propor-
tional areas to establish a normal donor standard spectratype. As expected, as 
we added more donors to the determination, the mean curves approached a 
more Gaussian-like distribution. 
  For each study subject, we then quantifi  ed the   “  divergence score  ”   of 
each V     family from its counterpart V     normal donor standard as the sum 
of the absolute value of the divergence in proportional area at each peak. 
Therefore, divergence scores were established for each V     family, for each 
patient, separately for CD4  +   and for CD8  +   cells, and for both at baseline 
(pre) and day 21 (post). We then tested the hypothesis that, for a given CD4  +   
or CD8  +   population in a given subject, the day 21 (post) divergence scores 
were signifi  cantly smaller than the baseline (pre) divergence scores in a non-
parametric Wilcoxon analysis (2-tailed). A P value   <  0.05 indicates a statisti-
cally signifi  cant increase in repertoire diversity toward normality between 
the baseline and day 21 studies 
  Finally, for each single V     family, we calculated a   “  diversity shift  ”   as the 
diff  erence between   “  pre  ”   and   “  post  ”   divergence scores, and we calculated 
the median of these diversity shifts (median diversity shift) for the set of 22 
V     family of each T cell population (CD4  +   or CD8  +  ), a positive value indi-
cating a shift toward greater repertoire diversity. 
  Statistical analyses 
  Anti-CD3 proliferation.     We performed statistical analyses using GraphPad 
Prism version 4.0a for Macintosh (GraphPad Software). Signifi  cant diff  erences JEM VOL. 205, July 7, 2008 
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